SCHEMBL21943411

SCHEMBL21943411

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1Oc1nc(N2CC(C)OC(C)C2)nc2nn(C)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 13/20 0.53
LMNA P02545 2/20 0.53
YES1 P07947 2/20 0.53
DDR2 Q16832 2/20 0.53
ESYT2 A0FGR8 1/20 0.53
HACL2 A1L0T0 1/20 0.53
NBAS A2RRP1 1/20 0.53
GTPBP10 A4D1E9 1/20 0.53
CNOT1 A5YKK6 1/20 0.53
TBKBP1 A7MCY6 1/20 0.53
AGPS O00116 1/20 0.53
ACOT7 O00154 1/20 0.53
MYO1F O00160 1/20 0.53
SNAP23 O00161 1/20 0.53
HAX1 O00165 1/20 0.53
AIP O00170 1/20 0.53
AP3B1 O00203 1/20 0.53
PSMD11 O00231 1/20 0.53
PSMD12 O00232 1/20 0.53
PSMD9 O00233 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21943540 0.95 BRAF (0.50) BRAFLMNAYES1DDR2ESYT2
SCHEMBL21942995 0.89 RAF1 (0.61) BRAFLMNAYES1DDR2ESYT2
SCHEMBL21943537 0.89 LMNA (0.51) BRAFLMNAYES1DDR2ESYT2
SCHEMBL21942956 0.86 BRAF (0.53) BRAFLMNAYES1DDR2ESYT2
SCHEMBL21943354 0.85 BRAF (0.49) BRAFLMNAYES1RAF1SMN1; SMN2
SCHEMBL21942948 0.83 KDR (0.49) BRAFLMNAYES1ABL1SRC
SCHEMBL21943629 0.82 MAPK14 (0.65) BRAFLMNAYES1DDR2ESYT2
SCHEMBL21943713 0.81 RAF1 (0.58) BRAFLMNAYES1DDR2ESYT2
SCHEMBL21943725 0.80 ABL1 (0.78) BRAFLMNAYES1DDR2ESYT2
SCHEMBL21943510 0.79 RAF1 (0.51) BRAFLMNAPDGFRBDDR1RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof XIAMEN UNIVERSITY (CN) 2022-05-03 US disclosed
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF XIAMEN UNIVERSITY (CN) 2020-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF CYP4A11, CYP2D6, CYP3A43 BRAF 95/4885LMNA 1474/4885YES1 722/4885
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof CYP4A11, CYP2D6, CYP3A43 BRAF 95/4885LMNA 1474/4885YES1 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.